SCHEMBL29470947

SCHEMBL29470947

O=C(Cl)c1ccc(F)c(F)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 3/20 0.67
CES1 P23141 3/20 0.67
KCNQ3 O43525 4/20 0.47
KCNQ2 O43526 4/20 0.47
KCNE1 P15382 1/20 0.47
KCNQ1 P51787 1/20 0.47
KCNQ5 Q9NR82 1/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
CHRNA1 P02708 1/20 0.44
CHRNG P07510 1/20 0.44
CHRNB1 P11230 1/20 0.44
CHRNB2 P17787 1/20 0.44
SLC6A2 P23975 1/20 0.44
CHRNB4 P30926 1/20 0.44
CHRNA3 P32297 1/20 0.44
CHRNA4 P43681 1/20 0.44
SLC6A3 Q01959 1/20 0.44
CHRND Q07001 1/20 0.44
PLA2G7 Q13093 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL192962 1.00 CES2 (0.67) CES2CES1KCNQ3KCNQ2KCNE1
SCHEMBL4957103 0.82 ALDH1A1 (0.54) CES2CES1KCNQ3KCNQ2KCNE1
SCHEMBL3026551 0.82 KCNQ3 (0.51) CES2CES1KCNQ3KCNQ2KCNE1
SCHEMBL193605 0.82 KCNQ3 (0.51) CES2CES1KCNQ3KCNQ2KCNE1
SCHEMBL11669995 0.82 ALDH1A1 (0.54) CES2CES1KCNQ3KCNQ2KCNE1
SCHEMBL18707178 0.82 KDM4E (0.53) CES2CES1POLB
SCHEMBL13012035 0.80 CES2 (0.43) CES2CES1MEN1KMT2AALDH1A1
SCHEMBL789006 0.80 CES2 (0.43) CES2CES1KCNQ3KCNQ2KCNE1
SCHEMBL925050 0.80 HDAC1 (0.61) CES2CES1KCNQ3KCNQ2KCNE1
SCHEMBL146573 0.80 NPC1 (0.46) CES2CES1RAB9AALDH1A1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117624140-A CXCR4 antagonists, methods of making and uses thereof 杭州师范大学 2024-03-01 CN claimed
CN-113307768-B Quinolone derivative and preparation method and application thereof 中国农业科学院兰州畜牧与兽药研究所 2023-12-12 CN claimed
CN-112752837-B Natural killer cells 帝国理工学院创新有限公司 2026-05-15 CN disclosed
CN-122010767-A Haloalkyl bisamide compound and application thereof 山东熙霖生物科技有限公司 2026-05-12 CN disclosed
US-20250206753-A1 FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE ABBVIE INC. 2025-06-26 US disclosed
CN-120040420-A Heterocyclic-pyrazole amine derivatives, preparation method thereof and application thereof in resisting tubercle bacillus infection 中国医学科学院医药生物技术研究所 2025-05-27 CN disclosed
CN-119684287-A 4- (3- (Piperidin-4-yl) -1H-pyrazol-5-yl) -1H-pyrrole [2,3-b ] pyridine derivative, and preparation method and application thereof 烟台新药创制山东省实验室 2025-03-25 CN disclosed
CN-119528777-A Sulfonated monomer and preparation method thereof, polymer and proton exchange membrane 华为技术有限公司 2025-02-28 CN disclosed
CN-119060061-A Application of benzopyrimidine thioether compounds as STING protein small molecule inhibitors 浙江师范大学 2024-12-03 CN disclosed
CN-119039255-A 5-Hydroxy-3-methylfuran-2 (5H) -one derivative, preparation method and application thereof 安徽农业大学 2024-11-29 CN disclosed
WO-2024213044-A1 AZACYCLO-CARBONYL-FUSED RING DERIVATIVES AND USE THEREOF Beijing Double-Crane Runchuang Technology Co., Ltd. (CN) 2024-10-17 WO disclosed
CN-116478134-A SSRI/5-HT 1A Double-target antidepressant formylpiperidine compound and preparation method and application thereof 上海医药工业研究院有限公司 2023-07-25 CN disclosed
CN-114014824-B Application of heterocyclic compound 上海科技大学 2023-06-13 CN disclosed
CN-115819417-A Pyrazolopyridine derivatives as HPK1 modulators and their use for the treatment of cancer 因赛特公司 2023-03-21 CN disclosed
CN-115385902-A Benzimidazole compound and preparation method and application thereof 徐州医科大学 2022-11-25 CN disclosed
WO-2022246392-A1 CYCLIC AMIDE-CONTAINING PYRIDYL XANTHINES AS A 2B ANTAGONISTS PURNOVATE, INC. (US) 2022-11-24 WO disclosed
CN-109923114-B Pyrazolopyridine derivatives as HPK1 modulators and their use for the treatment of cancer 因赛特公司 2022-11-01 CN disclosed
CN-109195965-B Inhibitors of WDR5 protein-protein binding 普罗佩纶治疗公司 2022-07-26 CN disclosed
CN-114380762-A Isoxazoline hydrazide derivative and preparation method and application thereof 贵州大学 2022-04-22 CN disclosed
CN-114014824-A Application of heterocyclic compound 上海科技大学 2022-02-08 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250206753-A1 FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE VHL, BRDT, PAICS CES2 816/4885CES1 1353/4885KCNQ3 4207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.